Logotype for Merck KGaA

Merck (MRK) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Merck KGaA

Q3 2026 earnings summary

12 Nov, 2026

Executive summary

  • Q3 net sales rose 5.8% YoY to €5.627bn, with 5.1% organic growth; EBITDA pre increased 0.8% to €1.682bn. Growth was led by Life Science and Electronics.

  • FY 2026 guidance was raised for net sales, EBITDA pre and free cash flow, while reported earnings were pressured by a €366m CDMO impairment.

Financial highlights

  • Q3 reported sales growth comprised 5.1% organic growth, a 1.5-point FX contribution and a 0.8-point negative portfolio effect.

  • EBITDA pre was €1.682bn versus €1.669bn, up 0.8% reported and 0.4% organically; EPS pre was €2.32, unchanged YoY.

  • EBIT fell to €653m from €1.221bn; profit after tax was €450m versus €898m, and reported EPS was €1.04 versus €2.07.

  • Operating cash flow rose 9.4% to €1.660bn and free cash flow increased 22.7% to €1.317bn.

  • 9M sales rose 2.2% to €16.195bn; EBITDA pre increased 3.1% to €4.811bn and EPS pre rose 2.0% to €6.59.

Outlook and guidance

  • FY 2026 net sales guidance: €21.5bn–€21.9bn, with organic growth of 3%–4% and FX impact of -1% to 0%; EBITDA pre guidance: €6.2bn–€6.4bn, with organic growth of 3%–5%.

  • EPS pre guidance is €8.30–€8.70; free cash flow guidance increased to €2.3bn–€2.7bn.

  • Guidance assumes Bio-Techne contributes in December 2026 and no U.S. Mavenclad sales from November; EBITDA pre FX impact is forecast at -2% to 0%.

  • Segment sales guidance: Life Science €9.4bn–€9.6bn, Healthcare €8.5bn–€8.7bn and Electronics ~€3.6bn; Electronics organic growth guidance is 10%–11%.

  • FY 2026 capex on PPE is guided at €1.3bn–€1.5bn; the underlying tax rate is expected at 22%–24% from 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Merck